abstract provided is an oral solid preparation of an anti-tubercular compound drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. the compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. the oral compound solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin. fig.1 a coated tablet with coated core ----------------------------------------- -------------------------------------------------- ---------------- translation of the abstract patent summary: "solid oral formulation of the compound antituberculous drug and method of preparation thereof". An oral solid preparation of a compound antituberculous drug is provided, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a core-coated dragonfly or a three-layer coated dragonfly where the two active ingredients rifampicin and isoniazid do not come into direct contact. The oral solid compound preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.abstract provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. the compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. the compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin. fig.1 a coated tablet with coated core ----------------------------------------------------------------------------------------------------------- trad
